GSA Capital Partners LLP Cuts Stock Position in Keros Therapeutics, Inc. $KROS

by · The Markets Daily

GSA Capital Partners LLP reduced its stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 58.8% during the third quarter, HoldingsChannel reports. The fund owned 25,300 shares of the company’s stock after selling 36,155 shares during the period. GSA Capital Partners LLP’s holdings in Keros Therapeutics were worth $400,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of KROS. Vanguard Group Inc. grew its position in Keros Therapeutics by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock valued at $43,011,000 after purchasing an additional 87,129 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Keros Therapeutics by 260.8% during the third quarter. JPMorgan Chase & Co. now owns 171,941 shares of the company’s stock valued at $2,720,000 after buying an additional 124,287 shares during the last quarter. Cornerstone Investment Partners LLC bought a new stake in shares of Keros Therapeutics during the third quarter valued at approximately $176,000. Strs Ohio raised its holdings in Keros Therapeutics by 200.0% in the 3rd quarter. Strs Ohio now owns 28,200 shares of the company’s stock worth $446,000 after acquiring an additional 18,800 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Keros Therapeutics in the 3rd quarter worth approximately $103,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on KROS shares. TD Cowen raised Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Wells Fargo & Company lowered their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Zacks Research downgraded shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Finally, Oppenheimer reissued an “outperform” rating and issued a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.29.

Check Out Our Latest Report on Keros Therapeutics

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $15.22 on Thursday. The business’s fifty day moving average is $18.51 and its 200 day moving average is $17.09. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $22.55. The company has a market capitalization of $463.75 million, a PE ratio of 9.88 and a beta of 0.86.

About Keros Therapeutics

(Free Report)

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

Featured Articles

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report).